Next-generation sequencing reveals potential predictive biomarkers and targets of therapy for urothelial carcinoma in situ of the urinary bladder

Bacillus Calmette-Gu érin instillation following removal of the tumor is the first-line of treatment for urothelial carcinoma in situ (CIS), the precursor lesion of most muscle-invasive bladder cancers. Bacillus Calmette-Guérin therapy fails in>50% of cases and second-line radical cystectomy is associated with overtreatment and drastic lifestyle consequences. Given the need for alternative bladder-preserving therapies, we identified genomic alterations (GAs) in urothelial CIS having the potential to predict response to targeted therapies.

Source: American Journal of Pathology - November 13, 2019 Category: Pathology Authors: Stefan Garczyk, Nadina Ortiz-Br üchle, Ursula Schneider, Isabella Lurje, Karolina Guricova, Nadine Therese Gaisa, Eva Lorsy, Katharina Lindemann-Docter, Axel Heidenreich, Ruth Knüchel Tags: Regular Article Source Type: research